ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IPSC Century Therapeutics Inc

1.24
0.19 (18.10%)
08 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Century Therapeutics Inc NASDAQ:IPSC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.19 18.10% 1.24 1.18 1.25 1.17 1.04 1.05 745,288 00:58:47

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

26/11/2024 12:00pm

GlobeNewswire Inc.


Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart


From Nov 2024 to Jan 2025

Click Here for more Century Therapeutics Charts.

Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:

  • Autoimmune Disease Cell Therapy Panel: 3:00 PM ET
    • Presenter: Chad Cowan, Ph.D., Chief Scientific Officer
  • Fireside Chat: 4:30 PM ET
    • Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer

A live webcast of the fireside chat can be accessed on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit www.centurytx.com.

For More Information:

Investor Relations & Media Contacts

Century TherapeuticsKatja BuhrerSVP, Head of Corporate Affairs and Strategykatja.buhrer@centurytx.com 917-969-3438

Argot PartnersNoor Pahlavicentury@argotpartners.com 212-600-1902

1 Year Century Therapeutics Chart

1 Year Century Therapeutics Chart

1 Month Century Therapeutics Chart

1 Month Century Therapeutics Chart

Your Recent History

Delayed Upgrade Clock